A study of the focal adhesion kinase inhibitor GSK2256098 in patients with recurrent glioblastoma with evaluation of tumor penetration of [11C]GSK2256098-Reference-Cited by-同舟云学术

A study of the focal adhesion kinase inhibitor GSK2256098 in patients with recurrent glioblastoma with evaluation of tumor penetration of [11C]GSK2256098

Published:2018-05-17 Issue:12 Volume:20 Page:1634-1642
ISSN:1522-8517
Container-title:Neuro-Oncology
language:en
Short-container-title:

Author:

Brown Nicholas F¹²^ORCID,Williams Matthew³⁴,Arkenau Hendrik-Tobias²⁵,Fleming Ronald A⁶,Tolson Jerry⁶,Yan Li,Zhang Jianping⁷,Singh Rajendra⁸,Auger Kurt R⁸,Lenox Laurie⁸,Cox David⁹,Lewis Yvonne⁸¹⁰,Plisson Christophe¹⁰,Searle Graham¹⁰,Saleem Azeem¹⁰,Blagden Sarah¹¹,Mulholland Paul¹²

Affiliation:

1. NIHR UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust, London, UK

2. Department of Oncology, UCL Cancer Institute, London, UK

3. Computational Oncology Lab, Institute of Global Health Innovation, South Kensington Campus, Imperial College, London, UK

4. Radiotherapy Department, Charing Cross Hospital, London, UK

5. Sarah Cannon Research Institute UK, London, UK

6. GlaxoSmithKline, Research Triangle Park, Durham, North Carolina, USA

7. PAREXEL International, Durham, North Carolina, USA

8. GlaxoSmithKline, Collegeville, Pennsylvania, USA

9. GlaxoSmithKline Research & Development Ltd, Uxbridge, UK

10. Imanova Ltd, Centre for Imaging Sciences, London, UK

11. NIHR/Wellcome Trust Imperial CRF, Imperial Centre for Translational and Experimental Medicine, Hammersmith Hospital, London, UK